| Filed On | Filing |
|---|---|
| 13 Nov 2026 |
8-K: Results of Operations and Financial Condition
WOBURN, Mass., November 13, 2026 — Biofrontera Inc. (NASDAQ: BFRI) (“Biofrontera” or the “Company”), a biopharmaceutical company specializing in the development and commercialization of photodynamic therapy (PDT) in dermatology, today re... |
| 14 Sep 2026 |
8-K: Other Events
Ameluz used in conjunction with the RhodoLED lamp becomes the first and only photodynamic therapy approved in the United States to treat a skin cancer, creating an additional growth opportunity for Biofrontera’s photodynamic therapy plat... |
| 13 Aug 2026 |
8-K: Results of Operations and Financial Condition
WOBURN, Mass., August 13, 2026 — Biofrontera Inc. (NASDAQ: BFRI) (“Biofrontera” or the “Company”), a biopharmaceutical company specializing in the development and commercialization of photodynamic therapy (PDT) in dermatology, today repo... |
| 17 Jun 2026 |
8-K: Submission of Matters to a Vote of Security Holders
On June 11, 2026, Biofrontera Inc. (the “Company”) held its Annual Meeting of Stockholders (the “Annual Meeting”). Proxies for the Annual Meeting were solicited pursuant to Regulation 14A under the Securities Exchange Act of 1934, and th... |
| 14 May 2026 |
8-K: Results of Operations and Financial Condition
Woburn, MA (May 14, 2026) (GLOBE NEWSWIRE) — Biofrontera Inc. (NASDAQ: BFRI) (the “Company”), a biopharmaceutical company specializing in the development and commercialization of photodynamic therapy (PDT) in dermatology, today reported ... |
| 19 Mar 2026 |
8-K: Results of Operations and Financial Condition
Woburn, MA (March 19, 2026) (GLOBE NEWSWIRE) — Biofrontera Inc. (NASDAQ:BFRI) (the “Company”), a biopharmaceutical company specializing in the development and commercialization of photodynamic therapy (PDT) in dermatology, today reported... |
| 09 Mar 2026 |
8-K: Regulation FD Disclosure
Biofrontera Inc. Reports Positive Phase 2b Results Supporting Further Development of Ameluz® Photodynamic Therapy for moderate to severe Acne Vulgaris |
| 26 Feb 2026 |
8-K: Other Events
U.S. Patent Office Issues Final Written Decision Finding All Challenged Claims of Sun Pharma’s Patent 11,697,028 To Be Unpatentable |
| 09 Feb 2026 |
8-K: Regulation FD Disclosure
Biofrontera Announces Positive Results in Phase 3 Study of Ameluz® PDT for Actinic Keratoses on the Extremities, Neck, and Trunk, Meeting Primary Endpoint |
| 13 Jan 2026 |
8-K: Results of Operations and Financial Condition
Biofrontera Inc. Announces Record Preliminary Fourth Quarter 2025 Revenues between $17.0 Million and $17.5 Million, Representing Approximately 35% Year-Over-Year Growth |
| 07 Jan 2026 |
8-K: Notice of Delisting or Failure to Satisfy a Listing Rule
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. |
| 13 Nov 2025 |
8-K: Results of Operations and Financial Condition
November 13, 2025 (GLOBE NEWSWIRE) Woburn, MA — Biofrontera Inc. (NASDAQ:BFRI) (the “Company”), a biopharmaceutical company specializing in the development and commercialization of photodynamic therapy (PDT) in dermatology, today reporte... |
| 10 Nov 2025 |
8-K: Other Events
As described further below, on each of November 4, 2025 and November 6, 2025, Biofrontera Inc. (the “Company”) received a notice (the “November 4 Notice” and the “November 6 Notice,” respectively) from the Listing Qualifications staff of... |
| 07 Nov 2025 |
8-K: Entry into a Material Definitive Agreement; Completion of Acquisition or Disposition of Assets +1 more
Form of Bill of Sale and Assignment and Assumption Agreement |
| 24 Oct 2025 |
8-K: Entry into a Material Definitive Agreement; Completion of Acquisition or Disposition of Assets +2 more
THIS ASSET PURCHASE AGREEMENT (this “Agreement”) is made as of October 20, 2025, by and between Biofrontera AG, a German corporation (“AG”), Biofrontera Pharma GmbH, a German private limited liability company (“Pharma”), Biofrontera Bios... |
| 23 Oct 2025 |
8-K: Regulation FD Disclosure
Biofrontera Inc. acquires full U.S. rights to Ameluz® and RhodoLED®, including New Drug Application and associated patents, from former parent Biofrontera AG. |
| 19 Sep 2025 |
8-K: Submission of Matters to a Vote of Security Holders
On September 16, 2025, Biofrontera Inc. (the “Company”) held a Special Meeting of Stockholders (the “Special Meeting”). Proxies for the Special Meeting were solicited pursuant to Regulation 14A under the Securities Exchange Act of 1934, ... |
| 13 Aug 2025 |
8-K: Results of Operations and Financial Condition
Woburn, MA, Aug. 13, 2025 (GLOBE NEWSWIRE) — Biofrontera Inc. (NASDAQ:BFRI) (the “Company”), a biopharmaceutical company specializing in the development and commercialization of photodynamic therapy in dermatology, today reported financi... |
| 11 Aug 2025 |
8-K: Departure/Election of Directors or Officers; Compensation; Regulation FD Disclosure
This Employment Agreement (the “Agreement”) is made as of July 18, 2025 (the “Effective Date”), by and between Biofrontera, Inc, a Delaware corporation (the “Company”) having its principal office at 120 Presidential Way, Suite 330, Wobur... |
| 01 Jul 2025 |
8-K: Entry into a Material Definitive Agreement; Unregistered Sales of Equity Securities +2 more
This Securities Purchase Agreement (this “Agreement”) is dated as of June 27, 2025, by and among Biofrontera Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its s... |
Loading...